Akebia Therapeutics (AKBA) to Release Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $51.6670 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.02). Akebia Therapeutics had a negative net margin of 2.26% and a negative return on equity of 16.70%. The business had revenue of $57.62 million during the quarter, compared to analysts’ expectations of $48.37 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Price Performance

Shares of NASDAQ AKBA traded up $0.05 on Wednesday, hitting $1.50. The company’s stock had a trading volume of 1,113,637 shares, compared to its average volume of 2,952,183. Akebia Therapeutics has a 12-month low of $1.14 and a 12-month high of $4.08. The company has a market capitalization of $401.03 million, a price-to-earnings ratio of -74.71 and a beta of 0.35. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.55 and a quick ratio of 1.46. The stock has a 50 day moving average of $1.38 and a 200-day moving average of $1.60.

Wall Street Analyst Weigh In

AKBA has been the topic of several recent research reports. Wall Street Zen downgraded shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akebia Therapeutics in a report on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Akebia Therapeutics in a report on Friday, February 6th. Zacks Research raised shares of Akebia Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $4.00 price target on shares of Akebia Therapeutics in a report on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.67.

Insider Activity

In other news, CEO John P. Butler acquired 69,270 shares of Akebia Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The shares were acquired at an average price of $1.25 per share, with a total value of $86,587.50. Following the completion of the purchase, the chief executive officer owned 3,367,064 shares of the company’s stock, valued at approximately $4,208,830. This represents a 2.10% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Akebia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Cibc World Markets Corp purchased a new position in shares of Akebia Therapeutics during the fourth quarter valued at approximately $27,000. Caption Management LLC purchased a new position in shares of Akebia Therapeutics during the fourth quarter valued at approximately $40,000. Baird Financial Group Inc. lifted its stake in shares of Akebia Therapeutics by 23.0% during the first quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,000 shares during the period. Polymer Capital Management US LLC lifted its stake in shares of Akebia Therapeutics by 49.5% during the third quarter. Polymer Capital Management US LLC now owns 18,232 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 6,034 shares during the period. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Akebia Therapeutics during the second quarter valued at approximately $62,000. Hedge funds and other institutional investors own 33.92% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.